Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Jenn Lachey"'
Autor:
Blake Moses, Ashlyn Wheeler, Mike Dills, Samuel Cadena, Lorena Lerner, Jasbir Seehra, Jenn Lachey
Publikováno v:
HemaSphere, Vol 7, p e10730ab (2023)
Externí odkaz:
https://doaj.org/article/54978d612bff43cb8b0bd3e7e0832357
Autor:
Chia-Yu Wang, Emiliano Melgar-Bermudez, Diana Welch, Claire Tseng, Ffolliott Fisher, Samuel Cadena, Lorena Lerner, Jasbir Seehra, Jenn Lachey
Publikováno v:
HemaSphere, Vol 7, p e253136f (2023)
Externí odkaz:
https://doaj.org/article/ec8eba71ac5e4e17b24156f1bdd1291c
Autor:
Blake S Moses, Chris Materna, Remya Nathan, Tandicka Nurse, Keith Babbs, Claire Tseng, Ffolliott Fisher, Jasbir Seehra, Jenn Lachey
Publikováno v:
Blood. 140:9763-9764
Autor:
Chia-Yu Wang, Emiliano Melgar-Bermudez, Diana Welch, Claire C Tseng, Ffolliott Fisher, Samuel M Cadena, Lorena Lerner, Jasbir Seehra, Jenn Lachey
Publikováno v:
Blood. 140:5337-5338
Autor:
Vera Hoving, Albertine Donker, Enrikas Vainorius, Harveen Dhillon Natarajan, Jenn Lachey, Simon Cooper, Dorine W. Swinkels, Saskia Schols
Publikováno v:
Blood. 140:2475-2476
Autor:
Jasbir Seehra, Jenn Lachey, Marina Feigenson, Joshua Lamora, Ffolliott Fisher, Claire C Tseng, Remya Nathan
Publikováno v:
Blood. 138:2068-2068
KER-050 is a modified ActRIIA ligand trap that is designed to inhibit the activity of the TGF-β ligands, including activin A, activin B, GDF8 and GDF11, that act through the SMAD2/3 signaling cascade. Notably, in a Phase 1 clinical study we observed
Autor:
Harveen Dhillon Natarajan, Alejandro Arbelaez, Ying Jiang, Chris Rovaldi, Chun Yew Fong, Tse-Chieh Teh, Claudia Ordonez, Hannah Rose, George Kannourakis, Adrienne Gaggi, John Kwan, David Westerman, Shuhying Tan, James Liang, Jenn Lachey, David M. Ross, Devendra K Hiwase, Lynette C.Y. Chee, Elissa Furutani, Joel Wight, Anish Puliyayil
Publikováno v:
Blood. 138:3675-3675
Background: Myelodysplastic syndromes (MDS) are characterized by ineffective hematopoiesis leading to cytopenias, including anemia and thrombocytopenia. KER-050, a modified activin receptor type IIA inhibitor, is designed to target transforming growt
Autor:
Ffolliott Fisher, Remya Nathan, Claire C Tseng, Joshua Lamora, Jasbir Seehra, Marina Feigenson, Jenn Lachey
Publikováno v:
Blood. 138:934-934
Myelofibrosis (MF) is characterized by the dysfunctional Janus kinase/signal transducers and activators of transcription signaling (JAK/STAT) pathways leading to progressive proliferation of granulocytic and megakaryocytic cells in the bone marrow at
Autor:
Marina Feigenson, Ffolliott Fisher, Claire C Tseng, Christopher Materna, Jenn Lachey, Evan Lema, Remya Nathan, Alana Gudelsky, Jasbir Seehra
Publikováno v:
Blood. 136:34-34
Diseases such as myelodysplastic syndrome (MDS) and myelofibrosis (MF) are characterized by ineffective hematopoiesis resulting in one or multiple cytopenias. Disease-causing defects occur across multiple cell lineages and stages of hematopoiesis, ma
Autor:
Remya Nathan, Marina Feigenson, Keith Babbs, Christopher Materna, Ffolliott Fisher, Claire C Tseng, Jasbir Seehra, Jenn Lachey
Publikováno v:
Blood. 136:38-38
Hemopoietic system control the production of circulating blood cells that have important functions from transport of oxygen and carbon dioxide, blood clotting to fighting infections. Not surprisingly, the system is tightly regulated and failure to re